Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Revenue
Research and collaboration revenue	$ 3,498	$ 652
Operating expenses
Research and development	38,202	38,817
General and administrative	17,357	14,923
Impairment of right-of-use asset	494	0
Total operating expenses	56,053	53,740
Loss from operations	(52,555)	(53,088)
Other (expense) income, net:
Interest income	2,174	1,330
Change in fair value of derivative tranche liability	(29,830)	0
Other expense	(192)	(33)
Total other (expense) income, net	(27,848)	1,297
Net loss	$ (80,403)	$ (51,791)
Net loss per share attributable to common stockholders, basic, (in USD per share)	$ (2.65)	$ (11.04)
Net loss per share attributable to common stockholders, diluted, (in USD per share)	$ (2.65)	$ (11.04)
Weighted-average shares of common stock outstanding, basic, (in shares)	30,380,567	4,690,094
Weighted-average shares of common stock outstanding, diluted, (in shares)	30,380,567	4,690,094
Net loss	$ (80,403)	$ (51,791)
Other comprehensive income (loss)	0	0
Total comprehensive loss	$ (80,403)	$ (51,791)